Narcotic Tapering in Pregnancy Using Long-acting Morphine: an 18-month Prospective Cohort Study in Northwestern Ontario

Overview

Journal Can Fam Physician

Specialties General Medicine
Public Health

Date 2015 Mar 31

PMID 25821873

Citations 11

Authors

Roisin Dooley

Joe Dooley

Irwin Antone

John Guilfoyle

Lianne Gerber-Finn

Kara Kakekagumick

Helen Cromarty

Wilma Hopman

Jill Muileboom

Nicole Brunton

Len Kelly

Affiliations

Soon will be listed here.

Abstract

Objective: To document the management of and outcomes for patients receiving narcotic replacement and tapering with long-acting morphine preparations during pregnancy.

Design: A prospective cohort study over 18 months.

Setting: Northwestern Ontario.

Participants: All 600 births at Meno Ya Win Health Centre in Sioux Lookout, Ont, from January 1, 2012, to June 30, 2013, including 166 narcotic-exposed pregnancies.

Intervention: Narcotic replacement and tapering of narcotic use with long-acting morphine preparations.

Main Outcome Measures: Prenatal management of maternal narcotic use, incidence of neonatal abstinence syndrome, and other neonatal outcomes.

Results: The incidence of neonatal abstinence syndrome fell significantly to 18.1% of pregnancies exposed to narcotics (from 29.5% in a previous 2010 study, P = .003) among patients using narcotic replacement and tapering with long-acting morphine preparations. Neonatal outcomes were otherwise equivalent to those of the nonexposed pregnancies.

Conclusion: In many patients, long-acting morphine preparations can be safely used and tapered in pregnancy, with a subsequent decrease in observed neonatal withdrawal symptoms.

Citing Articles

Addiction in the family: Two Indigenous families overcoming barriers to opioid agonist therapy.

Lawford K, Newman A Can Fam Physician. 2022; 68(5):348-351.

PMID: 35552202 PMC: 9097725. DOI: 10.46747/cfp.6805348.

Update of the Scientific Opinion on opium alkaloids in poppy seeds.

Knutsen H, Alexander J, Barregard L, Bignami M, Bruschweiler B, Ceccatelli S EFSA J. 2020; 16(5):e05243.

PMID: 32625895 PMC: 7009406. DOI: 10.2903/j.efsa.2018.5243.

Treatment of Opioid Use Disorder in Pregnant Women via Telemedicine: A Nonrandomized Controlled Trial.

Guille C, Simpson A, Douglas E, Boyars L, Cristaldi K, McElligott J JAMA Netw Open. 2020; 3(1):e1920177.

PMID: 32003816 PMC: 7042863. DOI: 10.1001/jamanetworkopen.2019.20177.

Opioids affect the fetal brain: reframing the detoxification debate.

Caritis S, Panigrahy A Am J Obstet Gynecol. 2019; 221(6):602-608.

PMID: 31323217 PMC: 8150872. DOI: 10.1016/j.ajog.2019.07.022.

Opioid Detoxification During Pregnancy: A Systematic Review.

Terplan M, Laird H, Hand D, Wright T, Premkumar A, Martin C Obstet Gynecol. 2018; 131(5):803-814.

PMID: 29630016 PMC: 6034119. DOI: 10.1097/AOG.0000000000002562.

References

Fischer G, Jagsch R, Eder H, Gombas W, Etzersdorfer P, Schatten C . Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction. 1999; 94(2):231-9. DOI: 10.1046/j.1360-0443.1999.9422317.x. View

Dooley J, Kelly L, St Pierre-Hansen N, Antone I, Guilfoyle J, ODriscoll T . Rural and remote obstetric care close to home: program description, evaluation and discussion of Sioux Lookout Meno Ya Win Health Centre obstetrics. Can J Rural Med. 2009; 14(2):75-9. View

McCarthy J . Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus?. J Matern Fetal Neonatal Med. 2011; 25(2):109-12. DOI: 10.3109/14767058.2011.600371. View

Ordean A, Kahan M . Comprehensive treatment program for pregnant substance users in a family medicine clinic. Can Fam Physician. 2011; 57(11):e430-5. PMC: 3215626. View

Kelly L, Dooley J, Cromarty H, Minty B, Morgan A, Madden S . Narcotic-exposed neonates in a First Nations population in northwestern Ontario: incidence and implications. Can Fam Physician. 2011; 57(11):e441-7. PMC: 3215628. View

Baewert A, Jagsch R, Winklbaur B, Kaiser G, Thau K, Unger A . Influence of site differences between urban and rural American and Central European opioid-dependent pregnant women and neonatal outcome characteristics. Eur Addict Res. 2012; 18(3):130-9. PMC: 3696360. DOI: 10.1159/000335082. View

Dow K, Ordean A, Murphy-Oikonen J, Pereira J, Koren G, Roukema H . Neonatal abstinence syndrome clinical practice guidelines for Ontario. J Popul Ther Clin Pharmacol. 2012; 19(3):e488-506. View

Stewart R, Nelson D, Adhikari E, Mcintire D, Roberts S, Dashe J . The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol. 2013; 209(3):267.e1-5. DOI: 10.1016/j.ajog.2013.05.026. View

Ferri M, Minozzi S, Bo A, Amato L . Slow-release oral morphine as maintenance therapy for opioid dependence. Cochrane Database Syst Rev. 2013; (6):CD009879. DOI: 10.1002/14651858.CD009879.pub2. View

10.

Kelly L, Guilfoyle J, Dooley J, Antone I, Gerber-Finn L, Dooley R . Incidence of narcotic abuse during pregnancy in northwestern Ontario: three-year prospective cohort study. Can Fam Physician. 2014; 60(10):e493-8. PMC: 4196835. View

11.

Kanate D, Folk D, Cirone S, Gordon J, Kirlew M, Veale T . Community-wide measures of wellness in a remote First Nations community experiencing opioid dependence: evaluating outpatient buprenorphine-naloxone substitution therapy in the context of a First Nations healing program. Can Fam Physician. 2015; 61(2):160-5. PMC: 4325865. View